The shifting sands of early stage R&D

Paul Overton, Aptuit’s Executive Vice President of business development and marketing, a scientist by background, talks to Jo Shorthouse of Scrip 100 Publication, about the evolving R&D model and how the CRO industry can work creatively on early stage research.

In this article, Paul discusses -

  • How the R&D paradigm needs to change in order to deliver more drugs to the market
  • If big pharma has been too slow to evolve to the R&D model
  • The key hurdles ahead of early stage research
Scrip 100 image.fw.png

Get your copy today!

Get the article